Market Trends of Immunohematology Industry
Immunohematology Analyzer Segment Expects to Witness Significant Growth Over the Forecast Period
Immunohematology analyzers are computerized, highly specialized, and automated machines that study the RBC antigens and antibodies associated with blood transfusion. The immunohematology analyzers segment is anticipated to witness significant growth in the immunohematology market over the forecast period owing to factors such as the rising burden of blood disorders, increasing technological advancements, and rising adoption rates of automated immunohematology instruments.
The rising incidence and prevalence of blood-related disorders, such as anemia, blood malignancies, hemorrhagic diseases, and blood-borne infections, among the population raise the demand for hematological testing. Thus, several studies have been conducted to compare the efficacy and accuracy of automated immunohematology analyzers. For instance, according to an article published in Transfusion and Apheresis Science in October 2022, it has been observed that a fully automated system such as ORTHO VISION Analyzer provides the transfusion medicine laboratory with important benefits of end-to-end process control (from sample load to result in output). In addition, about 2,631 immunohematology test profiles were evaluated, for ABO/Rh, antibody detection, antibody identification, crossmatch, and DAT, using the ORTHO VISION analyzer and its ORTHO optic reader system, and both systems showed accurate results. Also, the same source stated that the manual BioVue method frequently takes 1.5-3 times longer than the automated approach to produce final results. Thus, the high accuracy and speedy results offered by the immunohematology analyzers are expected to increase their adoption, thereby contributing to market growth.
Furthermore, the rising company activities in launching automated hematology analyzers in the region are also contributing to the market growth. For instance, in March 2021, Grifols, Barcelona, Spain, launched a DG Reader Net semiautomated analyzer used to facilitate pretransfusion blood type compatibility testing in North America. DG Reader Net, a compact and simple tool, automates the reading and interpretation of DG Gel cards, a method that determines the presence of certain antigens in red blood cells and is used to indicate blood type compatibility. The DG Reader Net analyzer offers laboratories computer-assisted reading and interpretation of immunohematology (IH) tests with automatic results uploaded to the laboratory information system.
Therefore, owing to the aforementioned factors, such as the rising number of research studies and new product launches, the studied segment is anticipated to grow over the forecast period.
North America is Expected to Have the Significant Market Share Over the Forecast Period
North America is anticipated to hold a significant share of the market over the forecast period owing to factors such as the increasing burden of immune-hematological disorders, traumas, and growing company activities.
The increasing cases of blood-related disorders are the major factors propelling the market growth in the region. For instance, according to the 2023 statistics published by the American Cancer Society, about 59,610 new cases of leukemia and 20,380 new cases of acute myeloid leukemia (AML) are expected to be diagnosed in the United States in 2023. Additionally, as per the 2022 statistics published by Myeloma Canada, about 4,000 new multiple myeloma cases are expected to be diagnosed in Canada in 2022. Thus, the high number of populations suffering from blood disorders raises the demand for blood transfusion, which requires antibody-antigen matching using immunohematology testing, hence propelling the market growth.
Furthermore, the rising company focus on adopting various key strategies such as agreements, partnerships, and product launches increases the availability of technologically advanced products in the market. This is anticipated to fuel the market growth over the forecast period. For instance, in February 2021, Beckman Coulter launched the DxH 560 AL, a tabletop hematology analyzer designed to reduce the time and resource constraints faced by small- to mid-sized laboratories. The users can add up to 50 samples continuously, protect against blood-borne diseases, and spend less time on manual instrument operations with the analyzer's auto-loading, closed tube aspiration, and walk-away features. Similarly, in November 2021, HealthTab Inc., a wholly owned subsidiary of Avricore Health Inc., signed a non-exclusive pilot supplier distribution agreement with Abbott, the global healthcare company, for the handheld blood chemistry analyzer i-STAT Alinity, in Canada.
Therefore, owing to the aforementioned factors, such as the high burden of blood disorders and new product launches, the studied market is anticipated to grow over the forecast period.
